Specific immunotherapy has long‐term preventive effect of seasonal and perennial asthma: 10‐year follow‐up on the PAT study

Jacobsen, Lars; Niggemann, B.; Dreborg, Sten; Ferdousi, Hosne Ara; Halken, Susanne; Høst, Arne; Koivikko, A.; Norberg, Lene Annette; Valovirta, Erkka; Wahn, Ulrich; Möller, Christian

doi:10.1111/j.1398-9995.2007.01451.x

Cited by 836 publications

(604 citation statements)

References 24 publications

Supporting

Mentioning

548

Contrasting

Unclassified

Order By: Relevance

“…For 147 children an evaluation was also performed seven years after SIT discontinuation. 31 The effect on asthma prevention was still persistent at this time.…”

Section: Special Focus Reviewmentioning

confidence: 94%

Specific immunotherapy in grass pollen allergy

Mailhol

Didier²

2012

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…For 147 children an evaluation was also performed seven years after SIT discontinuation. 31 The effect on asthma prevention was still persistent at this time.…”

Section: Special Focus Reviewmentioning

confidence: 94%

Specific immunotherapy in grass pollen allergy

Mailhol

Didier²

2012

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…Previous studies showed a reduction in long-term asthma risk among allergic rhinitic patients treated with SIT [68,69]. Meta-analyses show that this treatment could be beneficial in pollen-induced rhinitis and asthma, but state that more investigations are needed to determine its efficacy in house dust mite allergy [70].…”

Section: Treatmentmentioning

confidence: 99%

Asthma-related comorbidities

Boulet¹,

Boulay²

2011

Expert Review of Respiratory Medicine

213

139

View full text Add to dashboard Cite

“…Currently, allergen-specific immunotherapy (IT) is the only causative treatment that can affect the natural course of allergy and reduces the risk to develop allergic asthma (7). The goal of IT is to change the immune response to specific Ags, which results in long-term benefits even following the cessation of therapy (8).…”

mentioning

confidence: 99%

IL-10 and Regulatory T Cells Cooperate in Allergen-Specific Immunotherapy To Ameliorate Allergic Asthma

Böhm

Maxeiner

Meyer-Martin

et al. 2015

The Journal of Immunology

View full text Add to dashboard Cite

Human studies demonstrated that allergen-specific immunotherapy (IT) represents an effective treatment for allergic diseases. IT involves repeated administration of the sensitizing allergen, indicating a crucial contribution of T cells to its medicinal benefit. However, the underlying mechanisms of IT, especially in a chronic disease, are far from being definitive. In the current study, we sought to elucidate the suppressive mechanisms of IT in a mouse model of chronic allergic asthma. OVA-sensitized mice were challenged with OVA or PBS for 4 wk. After development of chronic airway inflammation, mice received OVA-specific IT or placebo alternately to airway challenge for 3 wk. To analyze the T cell–mediated mechanisms underlying IT in vivo, we elaborated the role of T-bet–expressing Th1 cells, T cell–derived IL-10, and Ag-specific thymic as well as peripherally induced Foxp3+ regulatory T (Treg) cells. IT ameliorated airway hyperresponsiveness and airway inflammation in a chronic asthma model. Of note, IT even resulted in a regression of structural changes in the airways following chronic inhaled allergen exposure. Concomitantly, IT induced Th1 cells, Foxp3+, and IL-10–producing Treg cells. Detailed analyses revealed that thymic Treg cells crucially contribute to the effectiveness of IT by promoting IL-10 production in Foxp3-negative T cells. Together with the peripherally induced Ag-specific Foxp3+ Treg cells, thymic Foxp3+ Treg cells orchestrate the curative mechanisms of IT. Taken together, we demonstrate that IT is effective in a chronic allergic disease and dependent on IL-10 and thymic as well as peripherally induced Ag-specific Treg cells.

show abstract

Specific immunotherapy has long‐term preventive effect of seasonal and perennial asthma: 10‐year follow‐up on the PAT study

Abstract: Specific immunotherapy has long-term clinical effects and the potential of preventing development of asthma in children with allergic rhino conjunctivitis up to 7 years after treatment termination.

Cited by 836 publications

References 24 publications

Specific immunotherapy in grass pollen allergy

Specific immunotherapy in grass pollen allergy

Asthma-related comorbidities

IL-10 and Regulatory T Cells Cooperate in Allergen-Specific Immunotherapy To Ameliorate Allergic Asthma

Contact Info

Product

Resources

About